Incidence Trend for Non-Hodgkin Lymphoma in the North Tunisian Population, 1998-2009

  • Benhassine, Adel (Department of Epidemiology and Biostatistics, Salah Azaiez Institute) ;
  • Khadhra, Hajer Ben (Department of Epidemiology and Biostatistics, Salah Azaiez Institute) ;
  • Khiari, Houyem (Department of Epidemiology and Biostatistics, Salah Azaiez Institute) ;
  • Hsairi, Mohamed (Department of Epidemiology and Biostatistics, Salah Azaiez Institute) ;
  • Elgaaied, Amel Benammar (Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences of Tunis, University Tunis El Mana)
  • Published : 2016.05.01


Background: In 2008, non-Hodgkin lymphoma ranked tenth among other malignancies worldwide with an incidence of around 5 cases per 100,000 in both genders. The latest available rates in Tunisia are from 2006. Materials and Methods: This study aimed to provide an update about NHL incidence for 2009 and its trend between 1998 and 2009 as well as a projection until 2024, using data from the Salah Azaiz Institute hospital registry and the Noth Tunisia cancer registry. Results: In 2009, the NHL incidence in the north of Tunisia was 4.03 cases per 100,000, 4.97 for men and 3.10 for women. Diffuse large B-cell lymphoma (DLBCL) accounted for 63.2% of all NHL subtypes. Between 1998 and 2009, the overall trend showed no significant change. When we compared the trend between two periods (1998-2005 and 2005-2009), joinpoint regression showed a significant decrease of NHL incidence in the first period with an annual percentage change (APC) of -6.7% (95% CI:[-11.2%;-2%]), then the incidence significantly increased from 2005 to 2009 with an APC of 30.5% (95% CI: [16.1%; 46.6%]. The analyses of the different subtype trends showed a significant decrease in DLBCL incidence between 1998 and 2000 (APC:-21.5; 95% CI: [-31.4%;-10.2%]) then the incidence significantly increased between 2004 and 2007 (APC: 18.5; 95% CI: [3,6%;35.5%]). Joint point analysis of the age-period-cohort model projection showed a significant increase between 2002 and 2024 with an APC of 4.5% (%95 CI: [1.5%; 7.5%]). The estimated ASR for 2024 was 4.55/100 000 (95% CI: [3.37; 6.15]). Conclusions: This study revealed an overall steady trend in the incidence of NHL in northern Tunisia between 1998 and 2009. Projection showed an increase in the incidence in NHL in both genders which draw the attention to the national and worldwide burden of this malignancy.


Incidence;malignant non-Hodgkin lymphoma;large B-cell diffuse lymphoma;trend


  1. Adamson P, Bray F, Costantini AS, et al (2007). Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer, 43, 391-401.
  2. Adeniji KA and Anjorin AS (2000). Peripheral lymphadenopathy in Nigeria. African J Med Medical Sci, 29, 233-37.
  3. Ahmedin J, Bray F, Ferlay J,Ward E, Forman D (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69-90.
  4. Ameen R, Sajnani KP, Albassami A, Refaat S (2010). Frequencies of non-Hodgkin's lymphoma subtypes in Kuwait: comparisons between different ethnic groups. Ann Hematol, 89, 179-84
  5. Anderson JR, Armitage JO, Weisenburger DD (1998). Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. non-hodgkin's lymphoma classification project. Ann Oncol, 9, 717-20.
  6. Baris D, Zahm SH (2000). Epidemiology of lymphomas. Curr Opin Oncol, 12, 383-94.
  7. Becker N, Deeg E, Rudiger T, Nieters A (2005). Medical history and risk for lymphoma: results of a population-based case-control study in Germany. Eur J Cancer, 41, 133-42.
  8. Campagna M, Cocco P, Zucca M, et al (2015). Risk of lymphoma subtypes and dietary habits in a Mediterranean area. Cancer Epidemiol, 39, 1093-8
  9. Cancer Mondial (2008). Lyon, France: International Agency for Research on Cancer, 2008.
  10. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H.Trends in cancer incidence and mortality. IARC Sci Pub, l1993, 1-806.
  11. Curado MP (2007). International Association of Cancer Registries. Cancer incidence in five continents, Vol. IX. Lyon, France: IARC Press, 2007.
  12. De Sanjose S, Dickie A, Alvaro T, et al (2004). Helicobacter pylori and malignant lymphoma in Spain. Cancer Epidemiol Biomarkers Prev, 13, 944-8.
  13. Devesa SS, Fears T (1992). Non-hodgkin's lymphoma time trends: united states and international data (link is external). Cancer Res, 52, 5432-40.
  14. Elias Campo, Steven H. Swerdlow, Nancy L, et al (2011). The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, 117, 19.
  15. Engels EA, Pfeiffer RM, Goedert JJ, et al (2006). Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS, 20, 1645-54.
  16. Eusebi LH, Zagari RM, Bazzoli F (2014). Epidemiology of Helicobacter pylori infection. Helicobacter, 19, 1-5.
  17. Feldman RA (2001). Review article: would eradication of Helicobacter pylori infection reduce the risk of gastric cancer? Aliment Pharmacol Ther, 15, 2-5.
  18. Ferlay J, Bray F, Steliarova-Foucher E, Forman D (2014). Cancer incidence in five continents, CI5plus. IARC Cancer Base No. 9 Lyon: International Agency for Research on Cancer. 2014.
  19. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
  20. Fisher SG, Fisher RI (2004). The epidemiology of non-Hodgkin's lymphoma. Oncogene, 23, 6524-34.
  21. Forman D (2007). International association of cancer registries. cancer incidence in five continents, Vol. X. Lyon, France: IARC Press, 2007.
  22. Glaser SL, Lin RJ, Stewart SL, et al (1997). Epstein-barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer, 70, 375-82.<375::AID-IJC1>3.0.CO;2-T
  23. God JM, Haque A Burkitt Lymphoma: Pathogenesis and Immune Evasion, Oncol. 2010.
  24. Hardell L, Eriksson M (2003). Is the decline of the increasing incidence of non-Hodgkin lymphoma in Sweden and other countries a result of cancer preventive measures? Environ Health Perspect, 111, 1704-06.
  25. Hartge P, Devesa SS (1992). Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence. Cancer Res, 52, 5566-9.
  26. Herrinton LJ (1998). Epidemiology of the revised european american lymphoma classification subtypes. Epidemiol Rev, 20, 187-203.
  27. Hooper WC, Holman RC, Clarke MJ, Chorba TL (2001). Trends in non-Hodgkin lymphoma (NHL) and HIV-associated NHL deaths in the United States. Am J Hematol, 66, 159-66.<159::AID-AJH1039>3.0.CO;2-2
  28. Howlader N, Morton LM, Feuer EJ, Besson C, Engels EA (2016). Contributions of subtypes of non-hodgkin lymphoma to mortality trends. Cancer Epidemiol Biomarkers Prev, 25, 174-9.
  29. Ilic M, Ilic I (2014). Malignant lymphatic and hematopoietic neoplasms mortality in serbia, 1991-2010: a joinpoint regression analysis. Matsuo K, ed. PLoS ONE, 9, 109379.
  30. Johnston WT, Mutalima N, Sun D, et al (2014). Relationship between Plasmodium falciparum malaria prevalence, genetic diversity and endemic Burkitt lymphoma in Malawi. Scientific Reports, 17, 4. 3741.
  31. Jurgens V, Ess S, Cerny T, Vounatsou P (2014). A Bayesian generalized age-period-cohort power model for cancer projections. Stat Med, 33, 4627-36.
  32. Kim HJ, Fay MP, Feuer EJ, et al (2000). Permutation tests for joinpoint regression with applications to cancer rates. Stat Med, 19, 335-51.<335::AID-SIM336>3.0.CO;2-Z
  33. Kuo SH1, Cheng AL (2013). Helicobacter pylori and mucosaassociated lymphoid tissue: what's new. Hematol Am Soc Hematol Educ Program, 109-17.
  34. Marcos-Gragera R, Pollan M, Chirlaque MD, et al (2010). Attenuation of the epidemic increase in non-Hodgkin's lymphomas in Spain. Ann Oncol, 21, 90-6.
  35. Marcucci F, Spada E, Mele A, Caserta CA, Pulsoni A (2012). The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review. Am J Blood Res, 2, 18-28.
  36. Morton LM, Turner JJ, Cerhan JR, et al (2007). Proposed classification of lymphoid neoplasms for epidemiologic research from the pathology working group of the international lymphoma epidemiology consortium (InterLymph). Blood, 110, 695-708.
  37. Morton LM, Sampson JN, Cerhan JR, et al (2014). Rationale and design of the international lymphoma epidemiology consortium (interlymph) non-hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr, 48, 1-14.
  38. Mozaheb Z, Aledavood A, Farzad F (2012). Diet and non-Hodgkin's lymphoma risk. Pan Afr Med J, 12, 53.
  39. N. Clumeck, J. Sonnet, H (1984). Taelman, Acquired immunodeficiency syndrome in African patients. N Engl J Med, 310, 492-7.
  40. North American Association of Central Cancer Registries (NAACCR).
  41. Novelli S, Briones J, Sierra J (2013). Epidemiology of lymphoid malignancies: last decade update. Springerplus, 2, 70.
  42. Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E (2007). Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci, 7, 166-75.
  43. Park HJ, Park EH, Jung KW, et al (2012). Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. Korean J Hematol, 47, 28-38.
  44. Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F (1999). AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS, 13, 2563-70.
  45. Patel M, Philip V, Fazel F, "Human Immunodeficiency Virus Infection and Hodgkin's Lymphoma in South Africa: An emerging problem," Advances in Hematology, vol. 2011, Article ID 578163, 6 pages, 2011.
  46. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL (2005). Global epidemiology of HTLV-1 infection and associated diseases. Oncogene, 5, 6058-68.
  47. Roman E, Smith AG (2011). Epidemiology of lymphomas. Histopathol, 58, 4-14.
  48. Sandin S, Hjalgrim H, Glimelius B, et al (2006). Incidence of non-Hodgkin's lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was. Cancer Epidemiol Biomarkers Prev, 15, 1295-300.
  49. Shipp MA, Mauch PM, Harris NL (1997). Cancer principles & practice of oncology Vol. 3. DeVita Jr V.
  50. Smedby KE, Hjalgrim H (2011). Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Seminars Cancer Biol, 21, 293-8.
  51. Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al (2012). Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet, 380, 1840-50.
  52. Van Leeuwen MT, Turner JJ, Joske DJ, et al (2014). Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006. Int J Cancer, 135, 2146-56.
  53. Vasef MA, Medeiros LJ, Koo C, McCourty A, Brynes RK (1997). Cyclin D1 immunohistochemical staining is useful in distinguishing mantle cell lymphoma from other low-grade B-cell neoplasms in bone marrow. Am J Clin Pathol, 108, 302-7.
  54. Vineis P, Crosignani P, Sacerdote C, et al (1999). Hematopoietic cancer and peptic ulcer: a multicenter case-control study. Carcinogenesis, 20, 1459-63.
  55. Vose JM1, Chiu BC, Cheson BD, Dancey J, Wright J (2002). Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Hematol Am Soc Hematol Educ Program, 241-62.
  56. Willett EV, Morton LM, Hartge P, et al (2008). Non-hodgkin lymphoma and obesity: a pooled analysis from the interlymph consortium. Int J Cancer, 122, 2062-70.